Oncotelic Therapeutics, Inc. (OTLC)

Oncotelic Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	0.07	-	-	1.74
Gross Profit	-	-	0.07	-	-	1.74
Selling, General & Admin	0.31	0.38	0.57	4.85	5.47	5.02
Research & Development	-0	-	0.06	0.76	3.66	4.3
Operating Expenses	0.31	0.38	0.63	5.61	9.13	9.33
Operating Income	-0.31	-0.38	-0.56	-5.61	-9.13	-7.58
Interest Expense	-0.83	-0.86	-1.04	-2.97	-2	-2
Other Non Operating Income (Expenses)	-0.33	-0.26	-0.15	0.68	0.29	-0.05
EBT Excluding Unusual Items	-1.47	-1.49	-1.76	-7.91	-10.84	-9.63
Impairment of Goodwill	-3.2	-3.2	-6.08	-4.11	-	-
Gain (Loss) on Sale of Investments	-	-	0.01	-	-	-
Gain (Loss) on Sale of Assets	-	-	-	16.95	-	-
Other Unusual Items	-	-0.09	-0.37	-0.26	0.32	-0.34
Pretax Income	-4.67	-4.78	-8.21	4.68	-10.52	-9.97
Earnings From Continuing Operations	-4.67	-4.78	-8.21	4.68	-10.52	-9.97
Minority Interest in Earnings	0.25	0.26	0.3	0.42	1.13	0.47
Net Income	-4.41	-4.52	-7.9	5.09	-9.39	-9.5
Net Income to Common	-4.41	-4.52	-7.9	5.09	-9.39	-9.5
Shares Outstanding (Basic)	406	404	384	384	303	88
Shares Outstanding (Diluted)	406	404	384	457	303	88
Shares Change (YoY)	5.33%	5.29%	-16.01%	50.89%	244.02%	46.94%
EPS (Basic)	-0.01	-0.01	-0.02	0.01	-0.03	-0.11
EPS (Diluted)	-0.01	-0.01	-0.02	0.01	-0.03	-0.11
Gross Margin	-	-	100.00%	-	-	100.00%
Operating Margin	-	-	-806.96%	-	-	-435.69%
Profit Margin	-	-	-11290.13%	-	-	-545.86%
EBITDA	-	-	-0.55	-5.6	-9.06	-7.22
D&A For EBITDA	-	-	0.01	0.01	0.06	0.36
EBIT	-0.31	-0.38	-0.56	-5.61	-9.13	-7.58
Revenue as Reported	-	-	0.07	-	-	1.74

Updated Nov 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.